An observational study in Tuberculosis, sponsored by University of Leicester. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University of Leicester · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Tuberculosis with a site in United Kingdom — 8 open to participants now, 10 under way, none of them phase 3. Tuberculosis · United Kingdom.
Among the 66 studies in Tuberculosis with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2027, is one of 20 observational ones, and was the 66th registered.
1,173 studies on the registry are indexed under Tuberculosis; 176 are open to participants now.
Browse Tuberculosis studies →8 of the 66 studies in Tuberculosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Liverpool School of Tropical Medicine · Sites in United Kingdom
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+
University of Oxford · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
University of Oxford · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Queen Mary University of London · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 6 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 253 across 317 observational studies indexed under Tuberculosis.
Median enrollment 36 across the 46 interventional studies, 225 across the 20 observational. Of the 48 that completed or were terminated, 7 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 66 have an industry lead sponsor. The 10 most frequent:
University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.
University of Leicester has 1 study filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Tuberculosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07024836University College, LondonPRecision biomArker-Guided MAnagement of TuberculosIs Contacts: a Discrete Choice Experiment | 2026-12 |
| NCT06670755University of OxfordID93/GLA-SE Vaccination + BCG Challenge | 2027-07-31 |
| NCT06728930Queen Mary University of LondonEvaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 66 studies in Tuberculosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
HEAL-TB (Health and Economic After-effects in Leicester Tuberculosis cohort) is a prospective observational study examining recovery among adults with pulmonary and extrapulmonary tuberculosis (TB). The study aims to understand how physical health, mental health, quality of life, daily activity, work and economic wellbeing change during TB treatment and up to 12 months after treatment completion.
Participants may join the study at different stages, from diagnosis until six months after completing TB treatment, and will be followed prospectively until 12 months after treatment completion. The study uses questionnaires, lung function testing, the Incremental Shuttle Walk Test, wrist-worn activity monitoring and information collected during routine clinical care. No experimental treatment is provided and participants continue to receive their usual NHS care.
The study aims to describe recovery over time, compare recovery following pulmonary and extrapulmonary TB, and identify factors associated with persistent health problems or poorer recovery.
HEAL-TB is a single-centre prospective observational cohort study designed to characterise physical, psychological and socioeconomic recovery among adults with pulmonary and extrapulmonary tuberculosis. Participants may enter the cohort at different stages of the tuberculosis pathway, from diagnosis or early treatment until six months after treatment completion, and complete the assessments applicable from their point of enrolment onwards. Follow-up continues until 12 months after treatment completion.
The study combines patient-reported outcome measures with objective assessments of physical function and routinely collected clinical information. Outcomes include health-related quality of life, mental health, work productivity and socioeconomic wellbeing, perceived recovery, lung function, functional exercise capacity, physical activity, sedentary behaviour and sleep. Relevant clinical records, imaging reports and routine investigation results are also reviewed to provide information on disease severity, treatment, complications and recovery.
The study is primarily descriptive and exploratory. Recovery trajectories will be characterised over time, with exploratory comparisons between pulmonary and extrapulmonary tuberculosis. Clinical and disease-related characteristics will also be explored as potential predictors of persistent impairment and poorer recovery. The study is intended to improve understanding of recovery beyond treatment completion and inform future approaches to follow-up, rehabilitation and supportive care for people affected by tuberculosis.
Adults with pulmonary or extrapulmonary tuberculosis receiving care or follow-up through University Hospitals of Leicester NHS Trust. Participants may enter the cohort at different stages of the tuberculosis treatment and recovery pathway, from diagnosis until six months after treatment completion. Participants will be recruited through the UHL clinical tuberculosis service across Leicester Royal Infirmary, Glenfield Hospital and Leicester General Hospital and followed prospectively from enrolment until the applicable final assessment at 12 months after treatment completion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with pulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study.
Participants with extrapulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study.
Health-related quality of life measured by EQ-5D-5L
Health-related quality of life assessed using the EQ-5D-5L, including the EQ-5D-5L utility index and EQ Visual Analogue Scale (EQ VAS). Repeated measurements will be used to characterise changes in health-related quality of life during tuberculosis treatment and recovery.
Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion
Depressive symptoms measured by PHQ-9
Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery.
Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion
Anxiety symptoms measured by GAD-7
Anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery.
Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion
Lung function measured by spirometry
Pre-bronchodilator spirometry including FEV1, FVC, FEV1/FVC ratio and percent predicted values. Repeated measurements will be used to characterise lung-function trajectories during recovery.
Time frame: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
Physical activity measured by wrist-worn activity monitor
Wrist-worn activity monitoring over 7 days to measure daily physical activity, including steps per day and time spent sedentary and in different physical activity intensity levels.
Time frame: Study entry and applicable follow-up assessments through 6 months after treatment completion
Work productivity and activity impairment measured by WPAI
Work Productivity and Activity Impairment questionnaire assessing work time missed, impairment while working, overall work impairment and activity impairment. Repeated measurements will characterise changes in work productivity and activity during treatment and recovery.
Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion
Functional exercise capacity measured by Incremental Shuttle Walk Test
Functional exercise capacity assessed using the Incremental Shuttle Walk Test (ISWT), with total distance walked recorded in metres.
Time frame: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
Respiratory-specific quality of life measured by St George's Respiratory Questionnaire
Respiratory health status assessed using the St George's Respiratory Questionnaire in participants with pulmonary tuberculosis only, measuring respiratory symptoms, activity limitation and psychosocial impacts.
Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion
Participant-reported recovery from tuberculosis
Study-specific questions assessing whether participants consider themselves fully recovered from tuberculosis and how their perceived recovery has changed since the previous study visit.
Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion
Plan to share: No — There is currently no plan to make individual participant-level data publicly available. Study findings will be disseminated in aggregate form.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.
Of 123 non-industry observational studies under Tuberculosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 21 months is below that.
Counting every sponsor, half of 135 studies reached it within 36 months; a quarter within 21 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.